Jiangsu Wuzhong: Warns of stock trading risks, with a net profit loss of 44.4178 million yuan in the first half of 2025

Jiangsu Wuzhong announced a warning about stock trading risks due to significant legal and financial issues, facing the risk of delisting. In the first half of 2025, the net profit loss was 44.4178 million yuan, a year-on-year decrease of 281.63%. The company received a penalty notice from the China Securities Regulatory Commission on July 13, 2025, due to false records in the annual reports from 2020 to 2023, and has implemented a delisting risk warning. The shares held by the controlling shareholder have been frozen, and the balance of non-operating funds occupied by related parties remains unresolved at 1.693 billion yuan

ST SuWu warns of multiple delisting risks, with inflated performance from 2020 to 2023 crossing the red line

ST Jiangsu Wuzhong issued its thirteenth risk warning announcement, warning of the potential risk of significant illegal forced delisting. The company has been filed for investigation due to suspected information disclosure violations, with false records in the annual reports from 2020 to 2023, inflating revenue by more than 1.8 billion yuan in total. The company also faces multiple risks, including financial delisting, delisting due to par value, as well as operational risks such as fund occupation by the controlling shareholder and performance losses. The company has not yet received a formal penalty decision and reminds investors to invest rationally

ST Jiangsu Wuzhong hit the daily limit, performing a "ceiling" with a trading volume exceeding 40 million yuan

ST Jiangsu Wuzhong hit the daily limit down during trading, performing a "Heaven and Earth Board," currently reported at 1 yuan, with a transaction amount of 23.1941 million yuan

ST Jiangsu Wuzhong: Lincomycin Hydrochloride Injection passes the consistency evaluation of generic drugs

ST SuWu announced that its wholly-owned subsidiary Suzhou Pharmaceutical Factory's Lincomycin Hydrochloride Injection has passed the consistency evaluation of generic drugs by the National Medical Products Administration. This approval will help enhance the market competitiveness of the drug and have a positive impact on its market sales. According to the policy, drugs that meet the consistency evaluation will receive support in terms of medical insurance payments, and medical institutions should prioritize procurement